All News

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.

Adjuvant Opdivo significantly extended relapse-free survival in patients with resected stage advanced melanoma.

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Adding Kisqali to a nonsteroidal aromatase inhibitor continued to reduce recurrence risk and improve survival at five years in early breast cancer.

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

Lenvima and Keytruda with chemo did not help patients with metastatic esophageal squamous cell carcinoma live longer than Keytruda and chemotherapy alone.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

Home-based supervised physical activity has no major impact on fatigue and quality of life for patients with metastatic cancer receiving oral targeted therapy.

Gleevec remains effective in advanced gastrointestinal stromal tumors, with complete response or full tumor removal doubling median survival.

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder versus BCG alone.

Stephanie Wachtel told CURE that areola tattooing after HER2-positive breast cancer helped her feel whole again and reconnect with her creativity.

LiveLung, a nonprofit organization, invites the CSRA’s lung cancer community to its educational meeting.

Artificial intelligence (AI) is revolutionizing the way cancer is studied and treated.

Registration is now open for the National Caregivers Self-Care and Tools online educational event on November 7th, 2025 at 11AM Pacific Time.

Between paying for treatment, managing a reduced income, and understanding insurance, the financial side of cancer can feel overwhelming.

After decades of lymphedema, breast cancer survivor Nora Ambros finds relief through robot-assisted microsurgery at Hackensack University.

Paper Describes Successful Genetic Testing Program Offered at Sheila R. Veloz Breast Center